Search Results - "Bilen, M.A."

1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Shen, J., Pachynski, R., Nordquist, L.T., Adra, N., Bilen, M.A., Aggarwal, R., Reichert, Z., Schweizer, M., Iravani, A., Aung, S., Hessel, C., Tagawa, S.T.

Get full text

EE390 Healthcare Resource Utilization (HCRU) and Costs in Patients with Metastatic Urothelial Cancer (MUC) Who Received First-Line (1L) Treatment: Results from Impact UC II by Bilen, M.A., Diessner, B., White, J., Kirker, M., Liu, F., Nguyen, A., Gharibian, N., Devgan, G., Katzenstein, H., Bhanegaonkar, A.

Get full text

701P Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC by Bilen, M.A., Xi, A.D., Wong, A., Schroeder, A., Kim, R., Liu, F.X., Peng, J., Robinson, S., Bhanegaonkar, A.

Get full text

469P A phase I study of palbociclib in combination with cisplatin or carboplatin in advanced solid malignancies by Alese, O.B., Bilen, M.A., Hitron, E., Lewis, C., Collins, H.H., Scott, S., Carthon, B., Cao, Y., Switchenko, J.M., Harvey, R.D., Owonikoko, T.K.

Get full text

2369P Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH) by McGregor, B.A., Campbell, M.T., Huang, J., Xie, W., Bilen, M.A., Mortazavi, A., Ravi, P., Shah, A., Einstein, D., Sonpavde, G.P., McKay, R.R., Siefker-Radtke, A.O., Bellmunt, J., Choueiri, T.K.

Get full text

Characteristics, Treatment and Outcomes of Patients with Primary Urethral Cancer: A Multi-Center Review over Two Decades by Qian, D.C., Xu, K.M., Hartsell, L.M., Cimmino, C.B., Joshi, S.S., Filson, C.P., Master, V., Sanda, M.G., Nazha, B., Carthon, B., Bilen, M.A., Kucuk, O., Shelton, J.W., Patel, P.R., Jani, A., Remick, J.S., Eng, T.Y.

Get full text

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201 by Necchi, A, Pouessel, D, Leibowitz, R, Gupta, S, Fléchon, A, García-Donas, J, Bilen, M A, Debruyne, P R, Milowsky, M I, Friedlander, T, Maio, M, Gilmartin, A, Li, X, Veronese, M L, Loriot, Y

“…Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of…”
Get more information

1383P Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA) by Reisinger, R., Swami, U., Hernandez, E.J., Sayegh, N., Wesolowski, S., Kiedrowski, L., Coelho Barata, P.M., Nussenzveig, R., Lemmon, G., Bilen, M.A., Heath, E., Nandagopal, L., Babiker, H., Pal, S.K., Lilly, M.B., Maughan, B.L., Yandell, M., Sartor, O., Agarwal, N.

Get full text

PCN241 Treatment Pattern and Healthcare Resource Utilization (HRU) in Patients with Metastatic Urothelial Carcinoma (MUC) Among Medicare Fee-for-Service (FFS) Beneficiaries: Results from IMPACT UC by Bilen, M.A., Xi, A., Schroeder, A., Kim, R., Liu, F., Wong, A., Peng, J., Jones, B., Robinson, S.B., Bhanegaonkar, A.

Get full text

Bladder Preserving Chemoradiotherapy Compared To Surgery For Variants Of Urothelial Carcinoma And Tumors With Divergent Differentiation: An Analysis Of The National Cancer Database by Janopaul-Naylor, J., Zhong, J., Liu, Y., Zhang, C., Osunkoya, A.O., Joshi, S.S., Bilen, M.A., Carthon, B., Kucuk, O., Hartsell, L.M., Shelton, J.W., Jani, A.

Get full text

83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10 by Siefker-Radtke, A.O., Hoch, U., Loriot, Y., Balar, A.V., Bilen, M.A., Tannir, N.M., Cho, D.C., Choudhury, A., Chien, D., Yu, D., Currie, S.L., Novotny, J., Santiago, L., Tagliaferri, M.A., Zalevsky, J., Huddart, R.A.

Get full text

688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features by Coelho Barata, P.M., Gulati, S., Elliott, A., Rao, A., Burgess, E.F., McKay, R., Hammers, H.J., Gartrell, B., Darabi, S., Bilen, M.A., Geynisman, D., Dawson, N.A., Poorman, K., Zibelman, M., Zhang, T., Wei, S., Korn, W.M., Nabhan, C., Ryan, C.J., Heath, E.

Get full text

Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study by Campbell, M.T., Bilen, M.A., Duran, C., Altinmakas, E., Lim, Z., Shah, A., Jonasch, E., Tannir, N.

Get full text

1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era by Thouvenin, J., Alhalabi, O., Carlo, M., Carril Ajuria, L., Bakouny, Z., Martinez Chanza, N., Negrier, S., Campedel, L., Bilen, M.A., Borchiellini, D., Chahoud, J., Vano, Y-A., Lodi, M., Barthelemy, P., Viswanathan, S.R., Msaouel, P., Choueiri, T.K., Albiges, L., Tannir, N., Malouf, G.

Get full text

502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer by Bakouny, Z., Grover, P., Labaki, C., Awosika, J., Gulati, S., Hsu, C-Y., Bilen, M.A., Eton, O., Fecher, L., Hwang, C., Khan, H., McKay, R.R., Ruiz, E., Weissmann, L., Thompson, M.A., Shah, D., Warner, J., Shyr, Y., Choueiri, T.K., Wise-Draper, T.

Get full text

901O - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma by Hoimes, C.J., Rosenberg, J.E., Srinivas, S., Petrylak, D.P., Milowsky, M., Merchan, J.R., Bilen, M.A., Gupta, S., Carret, A.-S., Yuan, N., Melhem-Bertrandt, A., Flaig, T.

“…Platinum-based chemotherapy remains the standard of care for patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC). Despite the use…”
Get full text

EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma by Hoimes, C.J., Rosenberg, J.E., Srinivas, S., Petrylak, D.P., Milowsky, M., Merchan, J.R., Bilen, M.A., Gupta, S., Carret, A.-S., Yuan, N., Melhem-Bertrandt, A., Flaig, T.

Get full text

986P - Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours by Campbell, M.T., Xie, W., Shah, A.Y., Habra, M.A., Jimenez, C., Venkatesan, A.M., Bubley, G., McKay, R.R., Choueiri, T.K., McGregor, B.A., Killbridge, K.L., Mortazavi, A., Bilen, M.A.

“…Metastatic primary adrenal tumors include those of cortical origin (ACC) and medullary origin (malignant pheochromocytoma/paraganglioma (MP)). Given the rarity…”
Get full text

Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours by Campbell, M.T., Xie, W., Shah, A.Y., Habra, M.A., Jimenez, C., Venkatesan, A.M., Bubley, G., McKay, R.R., Choueiri, T.K., McGregor, B.A., Killbridge, K.L., Mortazavi, A., Bilen, M.A.

Get full text

Small Cell Carcinoma of the Prostate: A Report of Outcomes of Localized Disease using the National Cancer Database by Xu, K.M., Liu, Y., Gillespie, T., Osunkoya, A.O., Carthon, B., Bilen, M.A., Filson, C.P., Ogan, K., Patel, P.R., Shelton, J.W., Kucuk, O., Alemozaffar, M., Jani, A.

Get full text